Enveric Biosciences (ENVB) announced that on March 17, 2026, it received U.S. Patent No. 12,577,232 from the United States Patent and Trademark Office, USPTO, pertaining to its EVM301 Series of molecules. The EVM301 Series includes lead candidate, EB-003, being developed as potential treatments for mental health disorders.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENVB:
- Psychedelic: AtaiBeckley reports publication of BPL-003 study results
- Enveric Biosciences announces registration of five trademarks in Canada
- Psychedelic: AtaiBeckley reports EMP-01 met primary objective in Phase 2a trial
- Enveric Biosciences announces withdrawal of petition against patent
- Enveric Biosciences reports EB-003 receptor engagement assay data